Pepgen is a developer of bio pharmaceutical products. The company specializes in developing biopharmaceutical products for the prevention and treatment of autoimmune and viral disorders and conducts clinical studies and seeks to develop autoimmune, viral and inflammatory therapies. Founded in 2018, PepGen is backed by investors that include Innovate UK, RA Capital Management, University of Oxford, Oxford Sciences Innovation, and CureDuchenne Ventures.